Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has reported Q3 FY2026 operational progress across its anti-infective pipeline, led by a second US Army research agreement, continued dosing in its Indonesian Phase 3 trial and expanded patent protection in Brazil.
US Army collaboration expands
The company signed a second Cooperative Research and Development Agreement with the US Army Institute of Surgical Research to evaluate RECCE® 327 Gel for burn wound infections.
The study will assess R327G in a validated burn wound infection model targeting MRSA and Pseudomonas aeruginosa, two pathogens commonly associated with burn patients.
Indonesia Phase 3 dosing continues
Recce is continuing patient dosing in its registrational Phase 3 clinical trial for diabetic foot infections in Indonesia, with five clinical sites activated.
The trial is designed to enrol up to 310 patients, with an interim data readout planned at 155 patients. A positive readout could support an accelerated approval submission and potential commercial launch in 2026.
Patent portfolio strengthened
The company secured a Brazilian Family 4 patent for its RECCE® anti-infectives, extending protection in Brazil to 2041.
The patent covers R327 and RECCE® 529, including preparation processes and use in bacterial and viral infections across multiple treatment areas.
Cash position supported by R&D rebate
Recce ended the quarter with A$1.7 million in cash and recorded net operating cash inflows of A$1.6 million.
The company received a A$5.3 million R&D Tax Incentive rebate for FY2025 and expects a further A$3.5 million refund in coming weeks.
What’s next
Key near-term priorities include progressing the Indonesia Phase 3 diabetic foot infection trial, advancing US Department of War burn wound programs under 2 active CRADAs, and continuing licensing negotiations for its late-stage clinical assets.